: Admin : 2020-08-07
Novavax Inc said on Wednesday it has entered a supply and license agreement with the Serum Institute of India for the development and commercialization of its Covid-19 vaccine candidate.
The Indian drugmaker will have exclusive rights for the vaccine in India during the term of the deal and non-exclusive rights during the "Pandemic Period" in all countries other than those designated by the World Bank as upper-middle or high-income countries.
The deal was signed on July 30, according to an SEC filing by Novavax.
On Tuesday, Novavax reported that its experimental COVID-19 vaccine produced high levels of antibodies against the novel coronavirus in a small, early-stage clinical trial, and that it could start a large pivotal Phase III trial as soon as late September.
Disclaimer: This article is sourced from indiatoday.in without any changes in the contents thereof. Only the title has been edited by Meddco.com The facts and the opinions appearing in the article do not reflect and describe views of meddco.com
Meddco Covaxin diseases Infectious Disease COVID-19 Crisis coronavirus antibody tests Coronavirus infection coronavirus covid-19 coronavirus mask coronavirus vaccine pandemic coronavirus coronavirus in India coronavirus test covid-19 test coronavirus treatment covid-19 treatment therapies book appointment affordable treatment packages surgery packages doctor near me hospital near me hospitals doctor
No Comments